Prescribing patterns for treatment of acne vulgaris: A retrospective chart review at an urban public and private hospital
- PMID: 39954091
- PMCID: PMC11829896
- DOI: 10.1007/s00403-025-03900-0
Prescribing patterns for treatment of acne vulgaris: A retrospective chart review at an urban public and private hospital
Abstract
Background: Studies have found demographic differences in prescribing patterns for certain inflammatory conditions, including acne.
Objective: To investigate acne prescription patterns among patients seen in the private system (PS) and safety-net health care system (SNS) of the University of Southern California (USC).
Methods: This was a multisite, retrospective study of patients obtaining acne care at PS and SNS outpatient dermatology facilities in Los Angeles over a one-year period.
Results: Despite similar acne severity, SNS patients were less often prescribed azelaic acid, benzoyl peroxide/clindamycin, benzoyl peroxide/adapalene, sulfacetamide, topical dapsone, and salicylic acid than PS patients (p < 0.001). SNS patients received fewer prescriptions for oral medications including spironolactone, antibiotics, and isotretinoin (p < 0.001). Despite similar acne severity, non-White patients were less frequently prescribed topical retinoids (p = 0.003), benzoyl peroxide/clindamycin (p = 0.003), isotretinoin (p < 0.001) and spironolactone (p < 0.001) than White patients. Despite higher acne severity among Hispanics/Latinos, they were less often prescribed spironolactone and oral antibiotics than their non-Hispanic/Latino counterparts (p = 0.023).
Conclusions: Findings from this study highlight differences in acne prescribing patterns by race/ethnicity and hospital system, which can impact the ability of patients to have successful treatment of their acne and its sequelae.
Keywords: Acne; Acne prescriptions; Acne treatments; Health equity; Postinflammatory hyperpigmentation; Skin of color.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Patient consent: Not applicable. IRB approval status: This study was approved by the USC Institutional Review Board. #UP-20-01465. Competing interests: Dr. Elbuluk has served as a consultant, advisory board member, and/or speaker for Avita, Incyte, VisualDx, La Roche Posay, Beiersdorf, Eli Lilly, Galderma, Pfizer, L’Oreal, McGraw Hill, Dior, Medscape, Abbvie, Takeda, Sanofi. She has received royalties from McGraw-Hill. She has stock options in VisualDx. The remaining authors have no disclosures to report.
Figures
References
-
- Davis SA, Narahari S, Feldman SR et al (2012) Top dermatologic conditions in patients of color: an analysis of nationally representative data. J Drugs Dermatol 11(4):466–473 - PubMed
-
- Child FJ, Fuller LC, Higgins EM, Du Vivier AW (1999) A study of the spectrum of skin disease occurring in a black population in south-east London. Br J Dermatol 141(3):512–517. 10.1046/j.1365-2133.1999.03047.x - PubMed
-
- Dlova NC, Mankahla A, Madala N et al (2015) The spectrum of skin diseases in a black population in Durban, KwaZulu-Natal, South Africa. Int J Dermatol 54(3):279–285. 10.1111/ijd.12589 - PubMed
-
- Yin NC, McMichael AJ (2014) Acne in patients with skin of color: practical management. Am J Clin Dermatol 15(1):7–16. 10.1007/s40257-013-0049-1 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
